Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential

Deregulated activity of the Src tyrosine kinases leads to malignant transformation. Since the FDA approval of the tyrosine kinase inhibitor, imatinib, in 2001 for the treatment of chronic myeloid leukemia (CML), the number of these inhibitors together with Src tyrosine kinase inhibitors (STKIs) has...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	José Rivera-Torres, Esther San José
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2019-09-01
Sarja:	Frontiers in Pharmacology
Aiheet:	Src tyrosine kinase inhibitors dasatinib immunotherapy LGLs γδ T cells senescence
Linkit:	https://www.frontiersin.org/article/10.3389/fphar.2019.01011/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!